Literature DB >> 11313889

PTOV1, a novel protein overexpressed in prostate cancer containing a new class of protein homology blocks.

P Benedit1, R Paciucci, T M Thomson, M Valeri, M Nadal, C Càceres, I de Torres, X Estivill, J J Lozano, J Morote, J Reventós.   

Abstract

In a search for molecular markers of progression in prostate cancer by means of differential display, we have identified a new gene, which we have designated PTOV1. Semiquantitative RT-PCR has established that nine out of 11 tumors overexpress PTOV1 at levels significantly higher than benign prostatic hyperplasia or normal prostate tissue. The human PTOV1 protein consists almost entirely of two repeated blocks of homology of 151 and 147 amino acids, joined by a short linker peptide, and is encoded by a 12-exon gene localized in chromosome 19q13.3. A Drosophila melanogaster PTOV1 homolog also contains two tandemly arranged PTOV blocks. A second gene, PTOV2, was identified in humans and Drosophila, coding for proteins with a single PTOV homology block and unrelated amino- and carboxyl-terminal extensions. A 1.8-Kb PTOV1 transcript was detected abundantly in normal human brain, heart, skeletal muscle, kidney and liver, and at low levels in normal prostate. Immunocytochemical analysis and expression of chimeric GFP-PTOV1 proteins in cultured cells showed a predominantly perinuclear localization of PTOV1. In normal prostate tissue and in prostate adenomas, PTOV1 was undetectable or expressed at low levels, whereas nine out of 11 prostate adenocarcinomas showed a strong immunoreactivity, with a focal distribution in areas of carcinoma and prostatic intraepithelial neoplasia. Therefore, PTOV1 is a previously unknown gene, overexpressed in early and late stages of prostate cancer. The PTOV homology block represents a new class of conserved sequence blocks present in human, rodent and fly proteins.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313889     DOI: 10.1038/sj.onc.1204233

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  33 in total

1.  The activator-recruited cofactor/Mediator coactivator subunit ARC92 is a functionally important target of the VP16 transcriptional activator.

Authors:  Fajun Yang; Rosalie DeBeaumont; Sharleen Zhou; Anders M Näär
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

2.  PTOV1 is overexpressed in human high-grade malignant tumors.

Authors:  Sara Fernández; Jose L Mosquera; Lide Alaña; Alex Sanchez-Pla; Juan Morote; Santiago Ramón Y Cajal; Jaume Reventós; Inés de Torres; Rosanna Paciucci
Journal:  Virchows Arch       Date:  2010-12-23       Impact factor: 4.064

3.  HDAC6 and Ubp-M BUZ domains recognize specific C-terminal sequences of proteins.

Authors:  Ryan L Hard; Jiangxin Liu; Juan Shen; Pei Zhou; Dehua Pei
Journal:  Biochemistry       Date:  2010-11-29       Impact factor: 3.162

4.  PTOV1 enables the nuclear translocation and mitogenic activity of flotillin-1, a major protein of lipid rafts.

Authors:  Anna Santamaría; Elisabeth Castellanos; Valentí Gómez; Patricia Benedit; Jaime Renau-Piqueras; Juan Morote; Jaume Reventós; Timothy M Thomson; Rosanna Paciucci
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

5.  PTOV1 is associated with UCH-L1 and in response to estrogen stimuli during the mouse oocyte development.

Authors:  Yu-Wei Yao; Yan Shi; Zhe-Fu Jia; Ya-Hong Jiang; Zheng Gu; Jian Wang; Mohamad Aljofan; Zhao-Gui Sun
Journal:  Histochem Cell Biol       Date:  2011-06-16       Impact factor: 4.304

6.  A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells.

Authors:  Scott A Stuart; Stephane Houel; Thomas Lee; Nan Wang; William M Old; Natalie G Ahn
Journal:  Mol Cell Proteomics       Date:  2015-04-07       Impact factor: 5.911

7.  Increased PTOV1 expression is related to poor prognosis in epithelial ovarian cancer.

Authors:  Fei Guo; Liu Feng; Ji-Long Hu; Mei-Ling Wang; Peng Luo; Xiao-Ming Zhong; An-Mei Deng
Journal:  Tumour Biol       Date:  2014-10-01

8.  Structure and VP16 binding of the Mediator Med25 activator interaction domain.

Authors:  Erika Vojnic; André Mourão; Martin Seizl; Bernd Simon; Larissa Wenzeck; Laurent Larivière; Sonja Baumli; Karen Baumgart; Michael Meisterernst; Michael Sattler; Patrick Cramer
Journal:  Nat Struct Mol Biol       Date:  2011-03-06       Impact factor: 15.369

Review 9.  Mediator-dependent nuclear receptor function.

Authors:  Wei Chen; Robert G Roeder
Journal:  Semin Cell Dev Biol       Date:  2011-08-10       Impact factor: 7.727

10.  Prostate tumor overexpressed 1 expression in invasive urothelial carcinoma.

Authors:  Steffen Rausch; Jörg Hennenlotter; Marcus Scharpf; Katharina Teepe; Ursula Kühs; Stefan Aufderklamm; Simone Bier; Johannes Mischinger; Georgios Gakis; Arnulf Stenzl; Christian Schwentner; Tilman Todenhöfer
Journal:  J Cancer Res Clin Oncol       Date:  2016-01-08       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.